{
    "nctId": "NCT02001974",
    "briefTitle": "Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)",
    "officialTitle": "Phase Ib Pilot Study to Evaluate Reparixin in Combination With Chemotherapy With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)",
    "overallStatus": "COMPLETED",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 33,
    "primaryOutcomeMeasure": "Treatment-Emergent Adverse Events (TEAEs)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Female aged \u2265 18 years.\n2. Patients with histologic or cytologic diagnosis of breast cancer with evidence of metastatic disease with documented HER-2 negative status and eligible for treatment with paclitaxel.\n3. Patients with at least one baseline measurable lesion according to RECIST version 1.1 criteria.\n4. Zubrod (Eastern Co-operative Oncology Group \\[ECOG\\]) Performance Status (PS) of 0-1.\n5. An electrocardiogram (ECG) with no clinically significant abnormalities indicative of myocardial ischemia.\n6. Ongoing toxicity associated with prior anticancer therapy \u2264 grade 1 Common Terminology Criteria for Adverse Events (CTCAE version 4.03) with the exception of alopecia.\n7. Maximum of three prior chemotherapy lines for advanced breast cancer (not including neo/adjuvant chemotherapy). If prior treatment with paclitaxel, PD must have occurred \\> 12 months from the end of previous adjuvant treatment or for previous metastatic treatment no PD must have occurred during treatment or within 3 months of the end of treatment\n8. Life expectancy of at least three months.\n9. Patients must be able to swallow and retain oral medication (intact tablet).\n10. Able to undergo all screening assessments outlined in the protocol following written informed consent.\n11. Adequate organ function (defined by the following parameters):\n\n    1. Serum creatinine \\< 140 \u00b5mol/L or creatinine clearance \\> 60 mL/min.\n    2. Serum hemoglobin \u2265 9 g/dL; absolute neutrophil count \u2265 1.5 x 10\\*\\*9/L; platelets \u2265 100 x 10\\*\\*9/L.\n    3. Serum bilirubin \u2264 1.5 x upper normal limit (UNL).\n    4. Serum ALT, AST \u2264 2.5 x UNL but \u2264 5.0 x UNL in case of liver metastases; ALP \u2264 UNL but \u2264 1.5 x ULN in case of liver metastases; albumin within normal limits. If ALP is greater than 1.5 x UNL (in the presence of liver metastases) the liver isoenzyme fraction will be measured. Liver isoenzyme fraction (absolute value) must be \u2264 1.5 x UNL.\n12. No known hepatitis B virus (not due to immunization), hepatitis C virus, human immunodeficiency virus \u0399 and -\u0399\u0399 positive status.\n\nExclusion Criteria:\n\n1. Male.\n2. Pregnancy or lactation or unwillingness to use adequate method of birth control.\n3. HER-2 positive disease status.\n4. Less than four weeks since last chemotherapy, radiotherapy or prior investigational therapy. Less than two weeks since last hormone or immunotherapy or signal transduction therapy.\n5. Neurological or psychiatric disorders which may influence understanding of study and informed consent procedures.\n6. Active or uncontrolled infection.\n7. Malabsorption syndrome, disease significantly affecting gastrointestinal function.\n8. Hypersensitivity to:\n\n   1. paclitaxel\n   2. ibuprofen or to more than one non-steroidal anti-inflammatory drug.\n   3. medications belonging to the class of sulfonamides, such as sulfamethazine, sulfamethoxazole, sulfasalazine, nimesulide or celecoxib.\n9. Presence of brain metastases (this does not include primary brain tumors) or leptomeningeal disease.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}